ARTICLE | Finance
Alnara to Allena
Alnara execs, VCs launch oral enzyme play Allena focus on nephrology, urology
November 21, 2011 8:00 AM UTC
Investors hope Allena Pharmaceuticals Inc. will get an oral enzyme through early Phase II data with the $15 million series A round it raised last week.
The biotech was founded by two former executives of metabolic and inflammation company Alnara Pharmaceuticals Inc., which Eli Lilly and Co. (NYSE:LLY) acquired last year: Alexey Margolin, founder and former CEO of Alnara, and Robert Gallotto, the CBO...